Roche Reports Submission of sBLA to the US FDA for Tecentriq (atezolizumab) + Avastin (bevacizumab) to Treat Unresectable Hepatocellular Carcinoma
Shots:
- The sBLA is based on P-III IMbrave150 study involve assessing of Tecentriq (1200mg- IV) + Avastin (IV- 15 mg/kg) vs Sorafenib (PO- 400mg- bid) in 501 patients in a ratio 2:1 with unresectable HCC prior not treated with systemic therapies
- The P-III IMbrave150 study results: 42% reduction in risk of death; 41% reduction in risk of disease worsening or death; safety profile is consistent with the individual therapies- presented at ESMO201
- Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1 receptor. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity- by inhibiting VEGF related immunosuppression
Click here to read full press release/ article
Ref: Roche | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com